Preclinical findings highlight PLT012's first-in-class anti-CD36 mechanism of action that reprograms immune-metabolic pathways to suppress Tregs, enhance CD8 ⁺ T-cell responses, and induce durable tumor control; and Company advancing toward first IND for PLT012 EPALINGES, Switzerland, Oct....
Pilatus Biosciences to Present New Preclinical Data Highlighting PLT012's Ability to Induce Durable Anti-Tumor Immunity Through Immunometabolic Reprogramming of the Tumor Microenvironment at SITC 2025 Annual Meeting
Seeking Alpha / 23 hours ago 1 Views
Comments